Head-To-Head Survey: Positron (OTCMKTS:POSC) & Guided Therapeutics (OTCMKTS:GTHP)

Guided Therapeutics (OTCMKTS:GTHPGet Free Report) and Positron (OTCMKTS:POSCGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by insiders. Comparatively, 17.2% of Positron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Guided Therapeutics and Positron’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Guided Therapeutics $100,000.00 55.33 -$3.49 million N/A N/A
Positron $740,000.00 40.30 -$1.64 million N/A N/A

Positron has higher revenue and earnings than Guided Therapeutics.

Risk and Volatility

Guided Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Positron has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Guided Therapeutics and Positron’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guided Therapeutics N/A N/A -158.84%
Positron -222.99% N/A -65.25%

Analyst Recommendations

This is a summary of recent ratings and price targets for Guided Therapeutics and Positron, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guided Therapeutics 0 0 0 0 N/A
Positron 0 0 0 0 N/A

About Guided Therapeutics

(Get Free Report)

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

About Positron

(Get Free Report)

Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.

Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.